Kybella® in Houston
Our office is now offering a non-invasive treatment for your double chin! Recently approved by the FDA, KYBELLA® (deoxycholic acid) injection, contours and improves the appearance of moderate to severe submental fullness, sometimes referred to as “double chin.”
Submental fullness can impact a broad range of adults, including both men and women, and can be influenced by several factors such as aging, genetics and weight gain and is often resistant to diet and exercise alone. According to a survey by the American Society for Dermatologic Surgery, nearly as many consumers are bothered by submental fullness (68%) as by lines and wrinkles around the eyes (71%).
When injected into subcutaneous fat, KYBELLA® causes the destruction of fat cells. Once destroyed, those cells cannot store or accumulate fat.
The most common side effects are swelling, bruising, pain, numbness, redness and formation of small areas of firmness around the treatment area. KYBELLA® can cause serious side effects, including trouble swallowing and nerve injury in the jaw that can cause an uneven smile or facial muscle weakness.
What is Kybella® used for?
- To eliminate submental fullness due to submental fat.
- For reduction in “double chin.
- To contour the bulge under the chin caused by fat
Submental fullness, sometimes referred to as “double chin,” is a common, yet undertreated facial aesthetic condition. It can detract from an otherwise balanced and harmonious facial appearance, leading to an older and heavier look.
Submental fullness can impact a broad range of adults, including both women and men, and can be caused by aging, genetics and weight gain.
KYBELLA® (deoxycholic acid) injection is the first and only FDA-approved injectable drug that contours and improves the appearance of submental fullness due to submental fat.
KYBELLA® is indicated for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults.
The safe and effective use of KYBELLA® for the treatment of subcutaneous fat outside the submental region has not been established and is not recommended.
The safety profile of KYBELLA® is well-characterized. KYBELLA® has been the focus of a global clinical development program involving over 20 clinical studies with more than 2,600 patients worldwide, of which over 1,600 have been treated with KYBELLA® .
The most common adverse reactions were edema/swelling, hematoma/bruising, pain, numbness, erythema and induration.
You and your health care provider will customize your KYBELLA® treatment regimen, including how many treatments you need, based on your desired chin profile.
Many patients experience visible results in 2 to 4 treatment sessions. During these sessions, your HCP will administer KYBELLA® into the fat under your chin using multiple injections. Up to 6 treatment sessions may be administered spaced no less than one month apart.
When injected into the fat under your chin, KYBELLA® causes the destruction of fat cells. Once destroyed, those cells cannot store or accumulate fat. After the aesthetic response is achieved, retreatment with KYBELLA® is not expected.